<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120109008665N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-11-24</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of zingiber and acupressure on nausea and vomiting</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of zingiber and acupressure onchemotherapy induced nausea and vomiting (CINV) in patients with breast cancer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43703</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Assignment of samples to four groups (zingiber, acupressure, zingiber
placebo and placebo of acupressure) will be done randomly using random
blocks method. 10 blocks with 8 cases in each are created and every time
randomly a block will be selected. In this method, A: represent zingiber
group; B: acupressure; C: zingiber placebo; D: placebo of acupressure (false point).</study_design>
      <phase>3</phase>
      <hc_freetext>Nausea and Vomiting.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: All participants in Zingiber intervention group, after assuring the results of the tests, in addition to the routine interventions prescribed by the physician, receive Vomigone pills (500 mg) Produced by Dineh Pharmaceutical Company for the first day of chemotherapy, half an hour before the injection of chemotherapy drugs, and the next time, at 9 o'clock of the same day. Continue taking tablets twice a day at 9 am and 9 pm, 5 days after the completion of chemotherapy. If the patient is raised, within two hours, the drug will be re-used. Intervention 2: Intervention group: In the acupressure intervention group, in addition to the routine interventions prescribed by the physician, the acupressure wristbands will be closed in two hands for half an hour before starting the injection of drugs up to 5 days after the completion of chemotherapy in the neiguan (P6) point. Intervention 3: Control group: In the Zingiber placebo group, placebo tablets similar to Vomigone tablets (size, shape, color, taste and dosage but lacking the active ingredient) will be used. The method is similar to the Zingiber group. Intervention 4: Control group: In the acupressure placebo group, the wristbands will close on both sides of the arm on the wrist with a plastic point at the opposite point of the neiguan point (false point). The method of doing is similar to the acupressure group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hassan Babamohamadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Midwifery Faculty, Semnan University of Medical Sciences, 5 Kilometers of Damghan Road, Semnan, Iran</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3513138111</zip>
        <telephone>+98 23 3365 4192</telephone>
        <email>babamohammady2007@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hassan Babamohamadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Midwifery Faculty, Semnan University of Medical Sciences, 5 Kilometers of Damghan Road, Semnan, Iran</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3513138111</zip>
        <telephone>+98 23 3365 4192</telephone>
        <email>babamohammady2007@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Detection of breast cancer by an oncologist and pathologist
Age between 18 and 70 years
The normal values of hematological and biochemical laboratory values in the Zingiber group
The desire to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Sensitivity to Zingiber and its consumption over the past week (at first use)
The presence of sensitivity and ulcers or any skin problems at the site of use of acupressure wristband
Use of blood diluent such as Aspirin, Warfarin, Heparin, Plavix and ... in the Zingiber group.
Coagulation disorders (platelets less than 100,000/mm3, etc.) in the Zingiber group
Receiving radiotherapy and chemotherapy simultaneously
The diseases that lead to nausea and vomiting include liver, kidney, upper gastrointestinal cancer, acute hepatitis B, gastrointestinal obstruction, brain malignancies, high blood pressure, motion sickness, diabetes and electrolyte disorders such as hyponatremia and Hypokalemia
Use of alcohol and opium
The history of psychiatric problems in patients under treatment with acupressure wristband</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R11.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Nausea with vomiting, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: All participants in Zingiber intervention group, after assuring the results of the tests, in addition to the routine interventions prescribed by the physician, receive Vomigone pills (500 mg) Produced by Dineh Pharmaceutical Company for the first day of chemotherapy, half an hour before the injection of chemotherapy drugs, and the next time, at 9 o'clock of the same day. Continue taking tablets twice a day at 9 am and 9 pm, 5 days after the completion of chemotherapy. If the patient is raised, within two hours, the drug will be re-used.</i_keyword>
      <i_keyword>Intervention group: In the acupressure intervention group, in addition to the routine interventions prescribed by the physician, the acupressure wristbands will be closed in two hands for half an hour before starting the injection of drugs up to 5 days after the completion of chemotherapy in the neiguan (P6) point.</i_keyword>
      <i_keyword>Control group: In the Zingiber placebo group, placebo tablets similar to Vomigone tablets (size, shape, color, taste and dosage but lacking the active ingredient) will be used. The method is similar to the Zingiber group.</i_keyword>
      <i_keyword>Control group: In the acupressure placebo group, the wristbands will close on both sides of the arm on the wrist with a plastic point at the opposite point of the neiguan point (false point). The method of doing is similar to the acupressure group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of nausea and vomiting. Timepoint: Evaluation and measurements will be performed from the first day of chemotherapy up to 5 days after the completion of chemotherapy by the patient. Method of measurement: Morrow Assessment of Nausea and Emesis (MANE).</prim_outcome>
      <prim_outcome>Frequency of nausea and vomiting. Timepoint: Evaluation and measurements will be performed from the first day of chemotherapy up to 5 days after the completion of chemotherapy by the patient. Method of measurement: Morrow Assessment of Nausea and Emesis (MANE).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-17</approval_date>
        <contact_name>Ethics committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>Semnan University of Medical Sciences (SEMUMS), Vice Chancellor of Research and Technology , Bassij Blvd., Semnan, Iran Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
